Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Should we treat soft tissue injuries with Actovegin

Lee, Paul Yuh Feng, Kwan, Alvin P.L., Smith, Paul and Nokes, Leonard 2016. Should we treat soft tissue injuries with Actovegin. EC Orthopaedics 4 (4) , pp. 600-604.

[img]
Preview
PDF - Accepted Post-Print Version
Download (381kB) | Preview

Abstract

Actovegin is a biological drug produced from deproteinised hemodialysate of calf serum with over 50 years of history for its clinical use. There have been many in vitro studies to speculate its potential role and mechanism of action in cells; due to the nature of this drug and serum based culture techniques for most in vitro experiments, presumptuous conclusions and claims from these studies on performance enhancement should be cautiously interpreted. There have been well-designed human in vivo studies suggesting it does not enhance human performance, and has potentially good clinical applications to treat injuries, strokes and diabetes. Recently, evidence has emerged suggesting Actovegin has anti-inflammatory and anti apoptotic effects on injured tissues; further clinical research is needed to define these effects. This article also provides a narrative review of Actovegin summarizing outcomes from recent publications.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Engineering
Subjects: Q Science > Q Science (General)
R Medicine > R Medicine (General)
Uncontrolled Keywords: Actovegin, doping, soft tissue injury, treatment, sports, orthopaedics
Publisher: ECronicon Open Access
Last Modified: 03 Nov 2017 08:56
URI: http://orca.cf.ac.uk/id/eprint/96170

Actions (repository staff only)

Edit Item Edit Item

Full Text Downloads from ORCA for this publication

Top Downloads of this item by Country

Monthly Full Text Downloads of this item

More statistics for this item...